Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Benitec Biopharma Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 2Completed
A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
BB-401
Head and Neck Squamous Cell Carcinoma
NCT03433027Enrollment16StartMar 2018Primary CompletionDec 2018CompletionApr 2020 - Phase 1/2Recruiting
A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia
BB-301: Dose escalation phase 1b cohort 1, BB-301: Dose escalation phase 1b cohort 2
Oculopharyngeal Muscular Dystrophy
NCT06185673Enrollment30StartNov 2023Primary CompletionNov 2030est.CompletionNov 2040est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2 | Completed | BB-401 | NCT03433027 |
| Phase 1/2 | Recruiting | BB-301: Dose escalation phase 1b cohort 1, BB-301: Dose escalation phase 1b cohort 2 | NCT06185673 |